SLP - Simulations Plus, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
26.66
-0.28 (-1.04%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close26.94
Open26.92
Bid5.12 x 900
Ask28.25 x 1300
Day's Range26.32 - 27.20
52 Week Range16.70 - 27.33
Volume42,811
Avg. Volume47,409
Market Cap466.955M
Beta (3Y Monthly)0.22
PE Ratio (TTM)65.02
EPS (TTM)0.41
Earnings DateN/A
Forward Dividend & Yield0.24 (0.96%)
Ex-Dividend Date2019-04-23
1y Target Est25.00
Trade prices are not sourced from all markets
  • Business Wire5 days ago

    Cognigen Launches KIWI Version 4.0

    Cognigen Corporation, a Simulations Plus company (SLP) and a leading provider of population pharmacokinetic and pharmacodynamic modeling and simulation services, today announced that it has released Version 4.0 of its KIWI™ Pharmacometric Communication and Collaboration Platform. KIWI is a private cloud-based, validated platform to efficiently and consistently organize, process, visualize, evaluate, and communicate modeling and simulation results. Since the introduction of KIWI 1.0 in 2011, our mission has been to provide pharmacometricians with the most efficient analysis environment possible.

  • New Strong Buy Stocks for June 10th
    Zacks6 days ago

    New Strong Buy Stocks for June 10th

    New Strong Buy Stocks for June 10th

  • Why Fundamental Investors Might Love Simulations Plus, Inc. (NASDAQ:SLP)
    Simply Wall St.17 days ago

    Why Fundamental Investors Might Love Simulations Plus, Inc. (NASDAQ:SLP)

    I've been keeping an eye on Simulations Plus, Inc. (NASDAQ:SLP) because I'm attracted to its fundamentals. Looking at...

  • Business Wire26 days ago

    PMDA Adds Licenses of GastroPlus®

    Simulations Plus, Inc. (SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that it has received an order from the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan to add licenses to its GastroPlus® software suite. John DiBella, Lancaster division president for Simulations Plus, said: “The adoption of physiologically based pharmacokinetic (PBPK) modeling to support various applications during the drug development process has increased over the years, partly driven by encouragement from global regulatory agencies.

  • Business Wirelast month

    U.S. FDA Renews DILIsym Software Licenses

    DILIsym Services, Inc., a Simulations Plus company (SLP) and a leading provider of simulation and modeling software for pharmaceutical safety and efficacy, today announced that the U.S. Food and Drug Administration has renewed its multi-seat license for the company’s flagship quantitative systems toxicology (QST) modeling software, DILIsym®. The renewal provides DILIsym access to FDA employees across all FDA divisions.

  • Business Wirelast month

    Simulations Plus to Present at B. Riley FBR Investor Conference on May 22, 2019

    Simulations Plus, Inc. , a leading provider of software for pharmaceutical discovery and development, today announced that Shawn O’Connor, chief executive officer, will present at the 20th Annual B.

  • Simulations Plus (NASDAQ:SLP) Shareholders Have Enjoyed A Whopping 304% Share Price Gain
    Simply Wall St.last month

    Simulations Plus (NASDAQ:SLP) Shareholders Have Enjoyed A Whopping 304% Share Price Gain

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...

  • Business Wire2 months ago

    Lisa LaVange, PhD, Appointed to Board of Directors of Simulations Plus

    Simulations Plus, Inc. (SLP), the premier provider of simulation and modeling software and consulting services for all stages of pharmaceutical discovery and development, today announced the appointment of Dr. Lisa LaVange to the Company’s Board of Directors. With a distinguished career spanning more than 35 years, Dr. LaVange brings expertise in biostatistics and experience with academia, commercial organizations, including Quintiles, the largest pharmaceutical outsourcing services company in the U.S., and government regulators, including a senior position at the U.S. Food and Drug Administration (FDA).

  • Business Wire2 months ago

    FDA Purchases Bundle of ADMET Predictor® Licenses

    Simulations Plus, Inc. (SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that it has received an order from the U.S. Food and Drug Administration (FDA) for a 15-user license to its ADMET Predictor® software suite. The purchase was made by the Center for Tobacco Products to support research projects aimed at informing regulatory decision making. John DiBella, Lancaster division president for Simulations Plus, said: “For many years, the FDA has utilized our software across various departments, including the Office of Clinical Pharmacology, Office of Generic Drugs, and Office of Pharmaceutical Quality.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of SLP earnings conference call or presentation 9-Apr-19 8:15pm GMT

    Q2 2019 Simulations Plus Inc Earnings Call

  • Business Wire2 months ago

    Simulations Plus Releases ADMET Predictor® Version 9.5

    Simulations Plus, Inc. (SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that it has released version 9.5 of its flagship machine learning modeling platform, ADMET Predictor®.

  • Simulations Plus Inc (SLP) Q2 2019 Earnings Call Transcript
    Motley Fool2 months ago

    Simulations Plus Inc (SLP) Q2 2019 Earnings Call Transcript

    SLP earnings call for the period ending February 28, 2019.

  • Simulations Plus (SLP) Q2 Earnings and Revenues Surpass Estimates
    Zacks2 months ago

    Simulations Plus (SLP) Q2 Earnings and Revenues Surpass Estimates

    Simulations Plus (SLP) delivered earnings and revenue surprises of 20.00% and 4.59%, respectively, for the quarter ended February 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press2 months ago

    Simulations Plus: Fiscal 2Q Earnings Snapshot

    On a per-share basis, the Lancaster, California-based company said it had net income of 12 cents. The maker of software used in pharmaceutical research posted revenue of $8.5 million in the period. Simulations ...

  • Business Wire2 months ago

    Simulations Plus Reports Record Second Quarter FY2019 Revenue

    Quarterly Revenues Up 15%; Board of Directors Announces Quarterly Dividend of $0.06 Per Share

  • The Simulations Plus (NASDAQ:SLP) Share Price Has Gained 230%, So Why Not Pay It Some Attention?
    Simply Wall St.2 months ago

    The Simulations Plus (NASDAQ:SLP) Share Price Has Gained 230%, So Why Not Pay It Some Attention?

    Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put i...

  • Business Wire2 months ago

    Simulations Plus Sets Date for 2nd Quarter 2019 Earnings Release and Conference Call

    Simulations Plus, Inc. (SLP) announced today that it expects to file its quarterly report on Form 10-Q for the second quarter of its 2019 fiscal year, the period ended February 28, 2019, on Tuesday, April 9, 2019. The Company will host a conference call on April 9, 2019, at 4:15 p.m. Eastern Time. Simulations Plus, Inc., is a premier developer of drug discovery and development software as well as a leading provider of both preclinical and clinical pharmacometric consulting services for regulatory submissions.

  • Analysts Estimate Simulations Plus (SLP) to Report a Decline in Earnings: What to Look Out for
    Zacks2 months ago

    Analysts Estimate Simulations Plus (SLP) to Report a Decline in Earnings: What to Look Out for

    Simulations Plus (SLP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Has Simulations Plus, Inc. (NASDAQ:SLP) Improved Earnings Growth In Recent Times?
    Simply Wall St.4 months ago

    Has Simulations Plus, Inc. (NASDAQ:SLP) Improved Earnings Growth In Recent Times?

    Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! When Simulations Plus, Inc. (NASDAQ:SLP) released its most recent earningsRead More...

  • Top 4 Oil and Gas Penny Stocks for 2019
    Investopedia4 months ago

    Top 4 Oil and Gas Penny Stocks for 2019

    The oil and gas industry includes companies involved in the exploration, extraction, refining, transporting and marketing of oil and gas products. The oil and gas sector started 2018 off strong, coinciding with a rise in crude oil prices from around $50 to $70 per barrel.

  • Moving Average Crossover Alert: Simulations Plus
    Zacks5 months ago

    Moving Average Crossover Alert: Simulations Plus

    Simulations Plus, Inc. (SLP) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.

  • Something To Consider Before Buying Simulations Plus, Inc. (NASDAQ:SLP) For The 1.2% Dividend
    Simply Wall St.5 months ago

    Something To Consider Before Buying Simulations Plus, Inc. (NASDAQ:SLP) For The 1.2% Dividend

    A sizeable part of portfolio returns can be produced by dividend stocks due to their contribution to compounding returns in the long run. Historically, Simulations Plus, Inc. (NASDAQ:SLP) has paid Read More...

  • Business Wire5 months ago

    DILIsym Awarded $1.5 Million Phase II NIH Grant

    DILIsym Services, Inc., a Simulations Plus company (SLP) developing in silico modeling software, resources, and information for assisting the pharmaceutical industry to more efficiently develop safe and effective drug therapies, today announced it has been awarded $1.5 million from Phase II of its previously announced Fast-Track Small Business Innovation Research (SBIR) grant by the National Institutes of Diabetes and Digestive and Kidney Diseases (NIDDK). The second phase of the grant funding will support DILIsym Services’ continued development, validation, and testing of its RENAsym software for predicting drug-induced kidney injury.

  • Thomson Reuters StreetEvents5 months ago

    Edited Transcript of SLP earnings conference call or presentation 9-Jan-19 9:15pm GMT

    Q1 2019 Simulations Plus Inc Earnings Call

  • Business Wire5 months ago

    Simulations Plus Releases DDDPlus™ Version 6

    Simulations Plus, Inc. (SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, and chemicals industries, today announced that it has released version 6 of its in vitro dissolution modeling software, DDDPlus™. John DiBella, president of the Lancaster division, added: “The DDDPlus client base has steadily increased over the years, with several regulatory agencies now using the program to assess dissolution method and product specification questions.